ImMucin, a vaccine that targets a molecule present in 90 percent of all cancers, has been tested on humans for the first time, according to researchers who found that all the blood cancer patients tested in the trial had greater immunity to the disease after receiving the drug.
New Vaccine That Targets 90% of Cancers Shows Promising Results in Human Safety Trials
Current Status: Blessed (1)
Seeded on Tue Apr 10, 2012 9:57 PM
keyboard shortcuts: V vote up article J next comment K previous comment
